

published in the **Federal Register** as provided in section 207.21 of the Commission's rules, upon notice from the Department of Commerce ("Commerce") of affirmative preliminary determinations in the investigations under sections 703(b) or 733(b) of the Act, or, if the preliminary determinations are negative, upon notice of affirmative final determinations in those investigations under sections 705(a) or 735(a) of the Act. Parties that filed entries of appearance in the preliminary phase of the investigations need not enter a separate appearance for the final phase of the investigations. Industrial users, and, if the merchandise under investigation is sold at the retail level, representative consumer organizations have the right to appear as parties in Commission antidumping and countervailing duty investigations. The Secretary will prepare a public service list containing the names and addresses of all persons, or their representatives, who are parties to the investigations.

**Background**

On August 11, 2015, AK Steel Corporation (West Chester, Ohio), ArcelorMittal USA, LLC (Chicago, Illinois), Nucor Corporation (Charlotte, North Carolina), SSAB Enterprises, LLC (Lisle, Illinois), Steel Dynamics, Inc. (Fort Wayne, Indiana), and United States Steel Corporation (Pittsburgh, Pennsylvania) filed a petition with the Commission and Commerce, alleging that an industry in the United States is materially injured or threatened with material injury by reason of subsidized imports of hot-rolled steel from Brazil, Korea, and Turkey and LTFV imports of hot-rolled steel from Australia, Brazil, Japan, Korea, the Netherlands, Turkey, and the United Kingdom. Accordingly, effective August 11, 2015, the Commission, pursuant to sections 703(a) and 733(a) of the Tariff Act of 1930 (19 U.S.C. 1671b(a) and 1673b(a)), instituted countervailing duty investigation Nos. 701-TA-545-547 and antidumping duty investigation Nos. 731-TA-1291-1297 (Preliminary).

Notice of the institution of the Commission's investigations and of a public conference to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the **Federal Register** of August 18, 2015 (80 FR 50028). The conference was held in Washington, DC, on September 1, 2015 and all persons who requested the opportunity were permitted to appear in person or by counsel.

The Commission made these determinations pursuant to sections 703(a) and 733(a) of the Tariff Act of 1930 (19 U.S.C. 1671b(a) and 1673b(a)). It completed and filed its determinations in these investigations on September 25, 2015. The views of the Commission are contained in USITC Publication 4570 (October 2015), entitled *Certain Hot-Rolled Steel Flat Products from Australia, Brazil, Japan, Korea, the Netherlands, Turkey, and the United Kingdom*: Investigation Nos. 701-TA-545-547 and 731-TA-1291-1297 (Preliminary).

By order of the Commission.  
 Issued: September 25, 2015.

**Lisa R. Barton,**

*Secretary to the Commission.*

[FR Doc. 2015-24760 Filed 9-29-15; 8:45 am]

**BILLING CODE 7020-02-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Application: Cerilliant Corporation**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before November 30, 2015.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/ODXL, 8701 Morrisette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant

Administrator of the DEA Office of Diversion Control ("Deputy Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on July 15, 2015, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Schedule
3-Fluoro-N-methylcathinone (3-FMC) (1233)	I
Cathinone (1235)	I
Methcathinone (1237)	I
4-Fluoro-N-methylcathinone (4-FMC) (1238)	I
Pentdrone (alpha-methylaminovalerophenone) (1246)	I
Mephedrone (4-(Methyl-N-methylcathinone) (1248)	I
4-Methyl-N-ethylcathinone (4-MEC) (1249)	I
Naphyrone (1258)	I
N-Ethylamphetamine (1475)	I
N,N-Dimethylamphetamine (1480)	I
Fenethylamine (1503)	I
Aminorex (1585)	I
4-Methylaminorex (cis isomer) (1590)	I
Gamma Hydroxybutyric Acid (2010)	I
Methaqualone (2565)	I
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) (6250)	I
SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) (7008)	I
5-Fluoro-UR-144 and XLR11 [1-(5-fluoro-pentyl)-1H-indol-3-yl][2,2,3,3-tetramethylcyclopropyl]methanone (7011)	I
AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) (7012)	I
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) (7019)	I
AB-PINACA (N-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (7023)	I
THJ-2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalene-1-yl)methanone (7024)	I
AB-CHIMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) (7031)	I
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) (7035)	I
APINACA and AKB48 (N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide) (7048)	I

Controlled substance	Schedule	Controlled substance	Schedule	Controlled substance	Schedule
JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) (7081).	I	3,4-Methylenedioxy-N-ethylamphetamine (7404).	I	Dihydromorphine (9145) .....	I
SR-19 and RCS-4 (1-Pentyl-3[(4-methoxy)-benzoyl] indole (7104).	I	3,4-Methylenedioxyamphetamine (7405).	I	Heroin (9200) .....	I
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl) indole) (7118).	I	4-Methoxyamphetamine (7411) ...	I	Hydromorphanol (9301) .....	I
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) (7122).	I	5-Methoxy-N-N-dimethyltryptamine (7431).	I	Methyldesorphine (9302) .....	I
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (7144).	I	Alpha-methyltryptamine (7432) ....	I	Methyldihydromorphine (9304) ....	I
JWH-073 (1-Butyl-3-(1-naphthoyl)indole) (7173).	I	Bufotenine (7433) .....	I	Morphine methylbromide (9305) ..	I
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl) indole) (7200).	I	Diethyltryptamine (7434) .....	I	Morphine methylsulfonate (9306)	I
AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) (7201).	I	Dimethyltryptamine (7435) .....	I	Morphine-N-oxide (9307) .....	I
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) (7203).	I	Psilocybin (7437) .....	I	Normorphine (9313) .....	I
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) (7222).	I	Psilocyn (7438) .....	I	Pholcodine (9314) .....	I
5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) (7225).	I	5-Methoxy-N,N-diisopropyltryptamine (7439).	I	Acetylmethadol (9601) .....	I
Alpha-ethyltryptamine (7249) .....	I	N-Ethyl-1-phenylcyclohexylamine (7455).	I	Allylprodine (9602) .....	I
CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol] (7297).	I	1-(1-Phenylcyclohexyl)pyrrolidine (7458).	I	Alphacetylmethadol except levo-alphaacetylmethadol (9603).	I
CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol] (7298).	I	1-[1-(2-Thienyl)cyclohexyl]piperidine (7470).	I	Alphameprodine (9604) .....	I
Lysergic acid diethylamide (7315)	I	N-Benzylpiperazine (7493) .....	I	Alphamethadol (9605) .....	I
2,5-Dimethoxy-4-(n-propylthiophenethylamine (2C-T-7) (7348).	I	4-Methyl-alpha-pyrrolidinopropiophenone (4-mePPP) (7498).	I	Betacetylmethadol (9607) .....	I
Marihuana (7360) .....	I	2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D) (7508).	I	Betameprodine (9608) .....	I
Tetrahydrocannabinols (7370) .....	I	2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E) (7509).	I	Betamethadol (9609) .....	I
Parahexyl (7374) .....	I	2-(2,5-Dimethoxyphenyl) ethanamine (2C-H) (7517).	I	Betaprodine (9611) .....	I
Mescaline (7381) .....	I	2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C-I) (7518).	I	Dipipanone (9622) .....	I
2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2) (7385).	I	2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-H) (7519).	I	Hydroxypethidine (9627) .....	I
3,4,5-Trimethoxyamphetamine (7390).	I	2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N) (7521).	I	Noracymethadol (9633) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391).	I	2-(2,5-Dimethoxy-4-(n-propylphenyl) ethanamine (2C-P) (7524).	I	Norlevorphanol (9634) .....	I
4-Bromo-2,5-dimethoxyphenethylamine (7392).	I	2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C-T-4) (7532).	I	Normethadone (9635) .....	I
4-Methyl-2,5-dimethoxyamphetamine (7395).	I	MDPV (3,4-Methylenedioxypropylvalerone) (7535).	I	Trimeperidine (9646) .....	I
2,5-Dimethoxyamphetamine (7396).	I	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe) (7536).	I	Phenomorphan (9647) .....	I
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole (7398).	I	2-(4-chloro-2,5-dimethoxyphenyl) N-(2-methoxybenzyl) ethanamine (25C-NBOMe) (7537).	I	1-Methyl-4-phenyl-4-propionoxypiperidine (9661).	I
2,5-Dimethoxy-4-ethylamphetamine (7399).	I	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe) (7538).	I	Tilidine (9750) .....	I
3,4-Methylenedioxyamphetamine (7400).	I	Methylone (3,4-Methylenedioxy-N-methylcathinone) (7540).	I	Para-Fluorofentanyl (9812) .....	I
5-Methoxy-3,4-methylenedioxyamphetamine (7401).	I	Butylone (7541) .....	I	3-Methylfentanyl (9813) .....	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402).	I	Pentylone (7542) .....	I	Alpha-methylfentanyl (9814) .....	I
		alpha-pyrrolidinopentiophenone (a-PVP) (7545).	I	Acetyl-alpha-methylfentanyl (9815).	I
		alpha-pyrrolidinobutiophenone (a-PBP) (7546).	I	Beta-hydroxyfentanyl (9830) .....	I
		AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole) (7694).	I	Beta-hydroxy-3-methylfentanyl (9831).	I
		Acetyldihydrocodeine (9051) .....	I	Alpha-methylthiofentanyl (9832) ...	I
		Benzylmorphine (9052) .....	I	3-Methylthiofentanyl (9833) .....	I
		Codeine-N-oxide (9053) .....	I	Thiofentanyl (9835) .....	I
		Desomorphine (9055) .....	I	Amphetamine (1100) .....	II
		Codeine methylbromide (9070) ...	I	Methamphetamine (1105) .....	II
				Lisdexamfetamine (1205) .....	II
				Phenmetrazine (1631) .....	II
				Methylphenidate (1724) .....	II
				Amobarbital (2125) .....	II
				Pentobarbital (2270) .....	II
				Secobarbital (2315) .....	II
				Glutethimide (2550) .....	II
				Nabilone (7379) .....	II
				1-Phenylcyclohexylamine (7460)	II
				Phencyclidine (7471) .....	II
				1-Piperidinocyclohexanecarbonitrile (8603).	II
				Alphaprodine (9010) .....	II
				Cocaine (9041) .....	II
				Codeine (9050) .....	II
				Dihydrocodeine (9120) .....	II
				Oxycodone (9143) .....	II
				Hydromorphone (9150) .....	II
				Diphenoxylate (9170) .....	II
				Ecgonine (9180) .....	II
				Ethylmorphine (9190) .....	II
				Hydrocodone (9193) .....	II
				Levomethorphan (9210) .....	II
				Levorphanol (9220) .....	II
				Isomethadone (9226) .....	II
				Meperidine (9230) .....	II
				Meperidine intermediate-A (9232)	II
				Meperidine intermediate-B (9233)	II
				Meperidine intermediate-C (9234)	II
				Metazocine (9240) .....	II

Controlled substance	Schedule
Methadone (9250) .....	II
Methadone intermediate (9254) ...	II
Dextropropoxyphene, bulk (non-dosage forms) (9273).	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Levo-alphaacetylmethadol (9648) ..	II
Oxymorphone (9652) .....	II
Noroxymorphone (9668) .....	II
Racemethorphan (9732) .....	II
Alfentanil (9737) .....	II
Remifentanil (9739) .....	II
Sufentanil (9740) .....	II
Carfentanil (9743) .....	II
Tapentadol (9780) .....	II
Fentanyl (9801) .....	II

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

Dated: September 21, 2015.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator.*

[FR Doc. 2015-24748 Filed 9-29-15; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Manufacturer of Controlled Substances Registration: Noramco, Inc.**

**ACTION:** Notice of registration.

**SUMMARY:** Noramco, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Noramco, Inc. registration as a manufacturer of those controlled substances.

**SUPPLEMENTARY INFORMATION:** By notice dated April 14, 2015, and published in the **Federal Register** on April 22, 2015, 80 FR 22555, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801-4417 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted for this notice.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by

inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of controlled substances:

Controlled substance	Schedule
Codeine-N-oxide (9053) .....	I
Dihydromorphine (9145) .....	I
Morphine-N-oxide (9307) .....	I
Amphetamine (1100) .....	II
Methylphenidate (1724) .....	II
Phenylacetone (8501) .....	II
Codeine (9050) .....	II
Dihydrocodeine (9120) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Hydrocodone (9193) .....	II
Morphine (9300) .....	II
Oripavine (9330) .....	II
Thebaine (9333) .....	II
Opium extracts (9610) .....	II
Opium fluid extract (9620) .....	II
Opium tincture (9630) .....	II
Opium, powdered (9639) .....	II
Opium, granulated (9640) .....	II
Oxymorphone (9652) .....	II
Noroxymorphone (9668) .....	II
Tapentadol (9780) .....	II

The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers.

Dated: September 21, 2015.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator.*

[FR Doc. 2015-24747 Filed 9-29-15; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Notice of Lodging of Proposed Consent Decree Under the Clean Air Act**

On September 24, 2015, the Department of Justice lodged a proposed Consent Decree with the United States District Court of the Virgin Islands in the lawsuit entitled *United States of America v. Virgin Islands Water and Power Authority*, Civil Action No. 3:14-cv-00086.

The Consent Decree resolves Clean Air Act violations alleged in the Complaint filed by the United States on October 30, 2014. The violations alleged in the Complaint with respect to VIWAPA's St. Thomas facility include VIWAPA's failure to properly operate and/or maintain its water injection systems on its gas turbine units, failure to operate in compliance with NO<sub>x</sub>,

sulfuric acid mist, particulate matter and VOC emission limits, failure to operate in compliance with opacity limits, failure to perform required audits and maintain required quality data availability, failure to properly operate and calibrate the continuous emission monitoring systems (CEMS) for NO<sub>x</sub> and CO, failure to conduct stack testing every 30 months, and failure to properly report non-compliance. The violations alleged in the Complaint with respect to VIWAPA's St. John facility concern VIWAPA's failure to comply with the RICE NESHAP regulations, failure to timely submit a Title V renewal application and operation without a Title V permit, and failure to conduct stack testing every 30 months.

The Consent Decree requires VIWAPA to generate a high percentage of its KWh from liquid propane gas or liquid natural gas and renewables, to implement a spare parts inventory program, to control NO<sub>x</sub> emissions through improved operation of its water injection system, to maintain and operate continuous emissions monitoring systems on specified units, to operate a video camera system for visible emissions, to perform stack testing, and to conduct targeted self-audits and third party audits given its long term compliance problems. The Consent Decree also requires a \$1,300,000 penalty to be paid within two years of the Effective Date of the Consent Decree. The penalty amount was based upon VIWAPA's limited financial ability to pay a penalty.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the Consent Decree. Comments should be addressed to the Assistant Attorney General for the Environmental and Natural Resources Division, and should refer to *United States v. Virgin Islands Water and Power Authority*, DOJ Ref. # 90-5-2-1-10424. All comments must be submitted no later than thirty days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	Send them to:
By email .....	<i>pubcomment-ees.enrd@usdoj.gov.</i>
By mail .....	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department Web site: <http://>